Caribou Biosciences(CRBU)
$0.31-0.02 (-4.91%)
CRBU
Caribou Biosciences financials statements
$0.31
At close:-0.02 (-4.91%)
Want to see CRBU full AI Analyst Report?
Caribou Biosciences (CRBU) Ratios
1,001 Followers
Caribou Biosciences Ratios
CRBU's free cash flow for Q3 2026 was $-22.54M. For the 2026 fiscal year, CRBU's free cash flow was decreased by $-19.00K and operating cash flow was $-22.52M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.71 | 7.16 | 11.97 | 9.25 | 15.15 |
| Quick Ratio | 5.71 | 7.16 | 11.97 | 9.25 | 15.15 |
| Cash Ratio | 0.49 | 0.53 | 1.81 | 2.07 | 9.31 |
| Solvency Ratio | -2.72 | -2.41 | -1.54 | -1.31 | -1.21 |
| Operating Cash Flow Ratio | -4.37 | -4.51 | -3.30 | -3.23 | -1.26 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -125.56 |
| Net Current Asset Value | $ 92.04M | $ 159.01M | $ 275.03M | $ 187.35M | $ 336.66M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.08 | 0.06 | 0.07 | 0.00 |
| Debt-to-Equity Ratio | 0.22 | 0.10 | 0.07 | 0.09 | 0.00 |
| Debt-to-Capital Ratio | 0.18 | 0.09 | 0.07 | 0.08 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.44 | 1.24 | 1.17 | 1.24 | 1.14 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -246.93 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -8372.38 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.29 | 0.29 | 0.37 | 0.46 | 0.00 |
| Net Debt to EBITDA | -0.10 | -0.07 | 0.21 | 0.32 | 3.66 |
| Profitability Margins | |||||
| Gross Profit Margin | 67.34% | 60.71% | 89.78% | 73.71% | 89.75% |
| EBIT Margin | -1332.33% | -1492.04% | -336.63% | -717.28% | -693.83% |
| EBITDA Margin | -1299.67% | -1452.74% | -326.40% | -691.00% | -683.58% |
| Operating Profit Margin | -1220.49% | -1667.16% | -336.63% | -768.17% | -697.84% |
| Pretax Profit Margin | -1332.33% | -1492.04% | -295.49% | -717.28% | -693.92% |
| Net Profit Margin | -1327.40% | -1491.95% | -296.05% | -717.79% | -697.26% |
| Continuous Operations Profit Margin | -1327.40% | -1491.95% | -296.05% | -717.79% | -697.26% |
| Net Income Per EBT | 99.63% | 99.99% | 100.19% | 100.07% | 100.48% |
| EBT Per EBIT | 109.16% | 89.50% | 87.78% | 93.38% | 99.44% |
| Return on Assets (ROA) | -84.47% | -47.59% | -23.62% | -26.60% | -15.13% |
| Return on Equity (ROE) | -121.24% | -58.95% | -27.71% | -33.04% | -17.26% |
| Return on Capital Employed (ROCE) | -90.82% | -58.95% | -28.73% | -30.78% | -16.08% |
| Return on Invested Capital (ROIC) | -89.77% | -58.65% | -28.65% | -30.70% | -16.07% |
| Return on Tangible Assets | -84.47% | -47.59% | -23.62% | -26.60% | -15.13% |
| Earnings Yield | -99.75% | -103.83% | -24.13% | -26.04% | -7.36% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.75 | 3.07 | 8.93 | 2.97 | 1.18 |
| Payables Turnover | 0.63 | 1.59 | 1.13 | 3.18 | 0.25 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.46 | 0.25 | 0.85 | 0.40 | 1.96 |
| Asset Turnover | 0.06 | 0.03 | 0.08 | 0.04 | 0.02 |
| Working Capital Turnover Ratio | 0.07 | 0.04 | 0.13 | 0.05 | 0.05 |
| Cash Conversion Cycle | -481.65 | -111.40 | -282.21 | 8.02 | -1171.08 |
| Days of Sales Outstanding | 97.44 | 118.73 | 40.85 | 122.91 | 308.95 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 579.09 | 230.13 | 323.06 | 114.88 | 1480.03 |
| Operating Cycle | 97.44 | 118.73 | 40.85 | 122.91 | 308.95 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.19 | -1.53 | -1.26 | -1.50 | -0.54 |
| Free Cash Flow Per Share | -1.20 | -1.60 | -1.42 | -1.60 | -0.59 |
| Dividend Paid and CapEx Coverage Ratio | -81.67 | -21.25 | -8.03 | -14.09 | -10.42 |
| Capital Expenditure Coverage Ratio | -81.67 | -21.25 | -8.03 | -14.09 | -10.42 |
| Operating Cash Flow Coverage Ratio | -4.08 | -5.22 | -3.44 | -3.28 | -125.56 |
| Operating Cash Flow to Sales Ratio | -9.95 | -13.83 | -2.71 | -6.57 | -3.39 |
| Free Cash Flow Yield | -75.66% | -100.77% | -24.80% | -25.51% | -3.92% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.00 | -0.96 | -4.14 | -3.84 | -13.59 |
| Price-to-Sales (P/S) Ratio | 13.31 | 14.37 | 12.27 | 27.57 | 94.75 |
| Price-to-Book (P/B) Ratio | 1.22 | 0.57 | 1.15 | 1.27 | 2.34 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.32 | -0.99 | -4.03 | -3.92 | -25.52 |
| Price-to-Operating Cash Flow Ratio | -1.34 | -1.04 | -4.53 | -4.20 | -27.96 |
| Price-to-Earnings Growth (PEG) Ratio | 0.28 | -0.05 | 0.26 | -0.08 | 1.30 |
| Enterprise Value Multiple | -1.13 | -1.06 | -3.54 | -3.67 | -10.20 |
| Enterprise Value | 163.36M | 153.80M | 398.86M | 351.24M | 669.21M |
| EV to EBITDA | -1.13 | -1.06 | -3.54 | -3.67 | -10.20 |
| EV to Sales | 14.64 | 15.39 | 11.57 | 25.36 | 69.72 |
| EV to Free Cash Flow | -1.45 | -1.06 | -3.80 | -3.61 | -18.78 |
| EV to Operating Cash Flow | -1.47 | -1.11 | -4.28 | -3.86 | -20.58 |
| Tangible Book Value Per Share | 1.31 | 2.80 | 4.99 | 4.95 | 6.44 |
| Shareholders’ Equity Per Share | 1.31 | 2.80 | 4.99 | 4.95 | 6.44 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.12 | 0.11 | 0.47 | 0.23 | 0.16 |
| Net Income Per Share | -1.59 | -1.65 | -1.38 | -1.64 | -1.11 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.88 | 1.00 | 1.00 |
| Research & Development to Revenue | 9.81 | 13.02 | 3.25 | 5.94 | 5.44 |
| SG&A to Revenue | 3.40 | 4.65 | 1.12 | 2.74 | 0.00 |
| Stock-Based Compensation to Revenue | 1.14 | 1.67 | 0.40 | 0.00 | 0.36 |
| Income Quality | 0.75 | 0.93 | 0.91 | 0.91 | 0.49 |
Currency in USD

